论文部分内容阅读
目的分析超早期重组组织型纤溶酶原激活剂(rt-PA)静脉溶栓联合依达拉奉对急性脑梗死(ACI)患者的影响。方法选取2013年6月—2016年10月张家港市第一人民医院收治的ACI患者76例,采用随机数字表法分为对照组和观察组,每组38例。对照组患者给予超早期rt-PA静脉溶栓治疗,观察组患者给予超早期rt-PA静脉溶栓联合依达拉奉治疗。比较两组患者血管再通情况、治疗前后美国国立卫生研究院卒中量表(NIHSS)评分及Barthel指数(BI)、不良反应发生率。结果观察组患者血管再通情况优于对照组(P<0.05)。两组患者治疗前NIHSS评分及BI比较,差异无统计学意义(P>0.05);观察组患者治疗后NIHSS评分低于对照组,BI高于对照组(P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论超早期rt-PA静脉溶栓联合依达拉奉可有效提高ACI患者血管再通率,改善患者神经功能及日常生活活动能力,且安全性较高。
Objective To analyze the effect of ultra-early recombinant tissue plasminogen activator (rt-PA) intravenous thrombolysis combined with edaravone on patients with acute cerebral infarction (ACI). Methods Sixty-six patients with ACI admitted to Zhangjiagang First People’s Hospital from June 2013 to October 2016 were randomly divided into control group and observation group with 38 cases in each group. Patients in the control group were given ultra-early rt-PA intravenous thrombolysis. Patients in the observation group were given ultra-early rt-PA intravenous thrombolysis combined with edaravone. The vascular recanalization was compared between the two groups. NIHSS score, Barthel index (BI) and incidence of adverse reactions before and after treatment were compared between the two groups. Results The vascular recanalization in observation group was better than that in control group (P <0.05). NIHSS score and BI before treatment in the two groups were not significantly different (P> 0.05). NIHSS score in the observation group was lower than that in the control group after treatment, and BI was higher than that in the control group (P <0.05). Two groups of patients with adverse reactions, the difference was not statistically significant (P> 0.05). Conclusion Ultra-early rt-PA intravenous thrombolysis combined with edaravone can effectively improve the recanalization rate of ACI patients, improve patients with neurological function and daily living activity, and high safety.